Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 25, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure regarding shareholding changes within a specific employee retirement plan and does not contain financial performance data.
Material Changes
The only material change disclosed is a movement in the GlaxoSmithKline US Retirement Savings Plan ("the Plan") on April 21, 2006. The number of Ordinary Share ADRs held by the fund increased from 17,465,905 to 17,507,831 at a price of $53.14.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the Plan is a discretionary fund for employees and former employees, and that two directors, Dr. J P Garnier and Dr. T Yamada, are potentially interested in the shares held in the fund in the same capacity as other employees.
Key Facts for Investor Verification
- The filing reports a specific increase of 41,926 Ordinary Share ADRs in the US Retirement Savings Plan.
- The transaction price for the shares was $53.14.
- Directors Dr. J P Garnier and Dr. T Yamada are identified as potentially interested parties in the fund.
- No financial performance metrics or strategic updates are included in this specific report.